Off Editas’ shelves, iNK cell therapies float to Shoreline
Editas Medicine is offloading its iNK cell franchise and licensing out some gene editing tech to a private biotech that counts BeiGene and Gilead’s Kite as friends.
Shoreline Biosciences is buying EDIT-202 and another undisclosed iNK program as part of the deal. MiNK Therapeutics had also been vying for the preclinical solid tumor cell therapy, Endpoints News reported last fall.
The San Diego biotech also obtains certain manufacturing tech, an exclusive license to Editas’ so-called SLEEK gene editing knock-in tech and a non-exclusive license to the Boston-area biotech’s engineered AsCas12a enzyme.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 158,500+ biopharma pros reading Endpoints daily — and it's free.